Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | FAAH | O00519 | 11/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010254 | 0.89 | FAAH (0.51) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL27233659 | 0.88 | CYP3A4 (0.55) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL27209671 | 0.87 | GPR119 (0.49) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1011311 | 0.87 | GPR119 (0.49) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL27233589 | 0.85 | GPR119 (0.47) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1010369 | 0.85 | FAAH (0.53) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL27094615 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1011984 | 0.84 | FAAH (0.53) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1009416 | 0.84 | CYP3A4 (0.56) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL27233667 | 0.84 | FAAH (0.53) | CYP3A4CYP2D6FAAHGABRA1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NEUROPN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | ASTRIZI BIO, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NeuroPn Therapeutics, Inc. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073648-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073680-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROPN THERAPEUTICS INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115186-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | CHEK1, CHEK2, BUB3 | CYP3A4 3568/4885CYP2D6 2940/4885FAAH 1498/4885 |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | PDCD1, TP53, CHEK2 | CYP3A4 3768/4885CYP2D6 4456/4885FAAH 3812/4885 |
| US-20260083718-A1 | PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY | GLP1R, GIPR, GPR119 | CYP3A4 2493/4885CYP2D6 2043/4885FAAH 395/4885 |
| US-20260102393-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PARK7, FAAH | CYP3A4 1949/4885CYP2D6 1350/4885FAAH 3/4885 |
| US-20240140930-A1 | PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRPH, EPHX1, BCHE | CYP3A4 2031/4885CYP2D6 3357/4885FAAH 15/4885 |
| US-20240294516-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | CYP3A4 712/4885CYP2D6 1859/4885FAAH 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.